H.R. 2853 — Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2021

“To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.”